Alopecia and Hypoesthesia in Folliculotropic T-Cell Lymphocytosis.

Actas Dermosifiliogr (Engl Ed)

Pediatría, Centro de Salud de San Sadurniño, SERGAS, San Sadurniño, A Coruña, España.

Published: October 2019

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ad.2018.05.015DOI Listing

Publication Analysis

Top Keywords

alopecia hypoesthesia
4
hypoesthesia folliculotropic
4
folliculotropic t-cell
4
t-cell lymphocytosis
4
alopecia
1
folliculotropic
1
t-cell
1
lymphocytosis
1

Similar Publications

Leprosy is an uncommon chronic mycobacterial infection in the United States caused by . There are two major forms of the infection, lepromatous leprosy and tuberculoid leprosy, with borderline forms of each. Leprosy is even more uncommon in the Northeastern United States and can present with various symptoms and skin findings, including erythematous or hypopigmented patches or plaques with accompanying hypoesthesia or anesthesia, anhidrosis, or alopecia.

View Article and Find Full Text PDF

Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2-low advanced or metastatic gastric cancer: a multicenter real-world study.

BMC Cancer

December 2023

Department of Medical Oncology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, No. 127 Dongming Road, Jinshui District, Zhengzhou City, 450008, Henan Province, China.

Background: Novel ADC drugs provide a new therapeutic strategy for gastric cancer.The present study aimed to analyze the clinical efficacy and drug toxicities of disitamab vedotin (RC48) plus immune checkpoint inhibitors(ICIs) and RC48 as third-line therapies and beyond for advanced and metastatic gastric cancer patients.

Methods: This was an observational multicenter real-world study.

View Article and Find Full Text PDF
Article Synopsis
  • * This observational study examined the effectiveness and safety of RC48-ADC used alone or with PD-1 inhibitors in 38 patients with locally advanced or metastatic urothelial carcinoma from August 2021 to October 2022.
  • * Results indicated a promising overall response rate of 63.2% and a disease control rate of 89.5%. The median progression-free survival was 8.2 months, and while adverse events occurred, none were of Grade ≥3
View Article and Find Full Text PDF

Background: Keyhole neurosurgery is the notion of safely removing brain and skull base lesions through smaller and more precise openings that lessen collateral damage to the surrounding scalp, brain, blood vessels, and nerves. The traditional frontal and pterional approaches require large craniotomies and this predisposes patients to significant and avoidable morbidity. With the growing expectation for minimally invasive surgery, we present our experience with the supraorbital keyhole craniotomy for surgical lesions in the anterior cranial fossa and parasellar regions.

View Article and Find Full Text PDF

Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma.

Clin Cancer Res

January 2021

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China.

Purpose: To evaluate the efficacy and safety of RC48-ADC, a novel humanized anti-HER2 antibody conjugated with monomethyl auristatin E, in patients with HER2 locally advanced or metastatic urothelial carcinoma (mUC) refractory to standard therapies.

Patients And Methods: This was a phase II, open-label, multicenter, single-arm study of patients with HER2 (IHC status 3+ or 2+) locally advanced or mUC who previously failed at least one line of systemic chemotherapy. The primary endpoint was the objective response rate (ORR) assessed by a blinded independent review committee (BIRC).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!